Bacteria-Based Vaccines for HIV and Other Infections

This patent describes using specially engineered bacteria, like Salmonella, to create vaccines that teach the body to fight off viruses like HIV by showing it specific parts of the virus on the bacteria's surface.

What it covers

This patent describes a method for creating vaccine candidates using bacteria. Specifically, it focuses on HIV, where bacteria are engineered to express (display) parts of the HIV virus, called MPER-derived antigens, on their outer surfaces. This display uses a natural bacterial mechanism called Gram autotransporters. When these engineered bacteria are used to immunize mice, the mice produce antibodies in their blood and vaginal washes that can bind to the bacteria. Crucially, at least one of these bacterial candidates also causes the production of antibodies that can neutralize (stop) HIV activity. This approach includes using both killed whole bacteria and live *Salmonella* to deliver these antigens.

What it doesn't cover

• —Vaccines that do not use bacteria as the primary delivery platform for antigens.
• —Vaccines that rely on traditional methods like inactivated viruses, attenuated viruses, viral vectors, or mRNA technology.
• —Vaccine candidates targeting parts of the HIV virus other than MPER-derived antigens.
• —Vaccines that present antigens internally within a cell rather than on the bacterial surface.
• —Bacterial vaccine platforms that do not utilize Gram autotransporters for surface antigen expression.

The clever bit

The novelty lies in using common bacteria, like *Salmonella*, as a living or killed 'display system' to present specific viral antigens, such as the MPER region of HIV, directly on their surface. This allows the immune system to recognize and respond to these viral parts in a way that could lead to protective immunity.

Why it matters

This patent addresses the significant global challenge of developing an effective HIV vaccine. The proposed bacteria-based approach, particularly using *Salmonella*, offers the potential for an inexpensive and globally appropriate vaccine. Such a vaccine could be rapidly produced and deployed using existing technologies, which is critical for widespread access and impact in areas most affected by HIV.

Real-world examples

• 1.HIV vaccine research
• 2.Oral vaccine development
• 3.Bacterial vector vaccines
• 4.Mucosal immunity studies